The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer will be offering “OncoPanel” hybrid capture NGS- based testing of HR+/HER2- breast cancer cases, facilitating the on-label use of capivasertib (Truqap™).
Individuals with hormone receptor-positive, HER2-negative breast cancer with activating mutations in AKT1 or PIK3CA, or inactivating mutations in PTEN are eligible for treatment with capivasertib.
The OncoPanel test enables the accurate assessment of genomic variants (SNVs and small indels only) in 73 genes, including AKT1, PIK3CA and PTEN. This panel does not detect gross deletions and duplications (CNVs) which is a known mechanism of PTEN inactivation which reduces the sensitivity of this assay to PTEN mutations. Further details of the methods and the genes and regions covered by the OncoPanel can be found here.
OncoPanel based testing of HR+/ HER2- breast cancer cases can be ordered using the Solid Tumour Requisition – Molecular found on our Requisitions page. Additional information on this testing can be found in our memo.